News | Radiation Oncology | October 21, 2021

Highlights include presentations by external authors studying the effects of concurrent Tumor Treating Fields and chemoradiation for patients with newly diagnosed glioblastoma 

Novocure’s proprietary TTFields platform within the radiation oncology community.

October 21, 2021 — Novocure announced 15 presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting from Oct. 24 to Oct. 27 in Chicago. External authors prepared five of the presentations, three of which include new data, reflecting continued interest in Novocure’s proprietary TTFields platform within the radiation oncology community.

Two presentations will feature new data on the investigational use of concurrent TTFields and chemoradiation for patients with newly diagnosed glioblastoma (GBM). Another presentation will highlight new data on the effects of TTFields in combination with irradiation on human GBM cells.

“We and our partners are excited to present and see a variety of research on Tumor Treating Fields at ASTRO’s 2021 Annual Meeting,” said Ely Benaim, M.D., Novocure’s Chief Medical Officer. “We appreciate the opportunity to continue our partnership with the radiation oncology community in working to establish Tumor Treating Fields as an important treatment for solid tumors. We look forward to participating in the exchange of scientific information at one of the premier meetings for radiation oncologists.”

The following will be presented at the ASTRO 2021 Annual Meeting:

Poster Presentations

(2045) Mechanism of action of Tumor Treating Fields (TTFields) in combination with sorafenib for treatment of hepatocellular carcinoma. Lead author: S. Davidi. Presenter: E. Dor-On. 1:30 p.m. to 2:45 p.m. CDT Sunday, Oct. 24.

(2250) Comprehensive approaches to enhancing Tumor Treating Fields dose at the tumor. Lead author and presenter: Z. Bomzon. 4:45 p.m. to 6 p.m. CDT Sunday, Oct. 24.

(2251) Framework for dosimetry and treatment planning of TTFields. Lead author and presenter: Z. Bomzon. 4:45 p.m. to 6 p.m. CDT Sunday, Oct. 24.

(2252) Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord. Lead author and presenter: J. De Los Santos. 4:45 p.m. to 6 p.m. CDT Sunday, Oct. 24.

(2253) Creating computational models for planning TTFields treatment for tumors in the infratentorial brain. Lead author: Y. Glozman. Presenter: B. Berger. 4:45 p.m. to 6 p.m. CDT Sunday, Oct. 24.

(2257) Impact of model inaccuracy on dose estimation in TTFields therapy. Lead author and presenter: T. Marciano. 4:45 p.m. to 6 p.m. CDT Sunday, Oct. 24.

(2258) Treating spinal-cord tumors with TTFields – a simulation study. Lead author and presenter: A. Naveh. 4:45 p.m. to 6 p.m. CDT Sunday, Oct. 24.

(2259) Segmentation of the upper torso for lung cancer TTFields treatment planning. Lead author: O. Peles. Presenter: B. Berger. 4:45 p.m. to 6 p.m. CDT Sunday, Oct. 24.

(2454) Tumor Treating Fields synergistically enhances cell death in non-small cell lung and pancreatic cancer cells treated with the combination of radiation and chemo agents that interfere with DNA replication fork stability. Lead author: N. Karanam. Presenter: M. Story. 11 a.m. to 12:15 p.m. CDT Monday, Oct. 25.

(2504) Activated phosphoinositide 3-kinase/AKT/mTOR signaling confers resistance to Tumor Treating Fields (TTFields). Lead author: A. Klein-Goldberg. Presenter: M. Giladi. 11 a.m. to 12:15 p.m. CDT Monday, Oct. 25.

(2960) Impact of Tumor Treating Fields on DNA damage repair in mesothelioma. Lead author: H. Mumblat. Presenter: E. Dor-On. 3:30 p.m. to 4:45 p.m. CDT Tuesday, Oct. 26.

(3252) SPARE trial: Scalp sparing radiation with concurrent temozolomide and Tumor Treating Fields (200 kHz) for patients with newly diagnosed glioblastoma. Lead author and presenter: R.C. Miller. 1 p.m. to 2:15 p.m. CDT Wednesday, Oct. 27.

(3255) Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma may increase the rate of distant recurrence. Lead author: A. Ali. Presenter: M. Z. K. Niazi. 1 p.m. to 2:15 p.m. CDT Wednesday, Oct. 27.

(3264) Combination treatment of Irradiation and Tumor Treating Fields for human glioblastoma cells. Lead author and presenter: M. Stein. 1 p.m. to 2:15 p.m. CDT Wednesday, Oct. 27.

(3268) Concurrent TTFields (200 kHz) with chemoradiation for patients with newly diagnosed glioblastoma may increase the rate of pseudoprogression: analysis of a pilot clinical trial. Lead author and presenter: J. Taylor. 1 p.m. to 2:15 p.m. CDT Wednesday, Oct. 27.

All poster presentations will be held outside Room W375 in McCormick Place West.

For more information: www.novocure.com

Related Content

News | Image Guided Radiation Therapy (IGRT)

May 19, 2022 — Brainlab announced that clinicians at UZ Brussel are the first to treat patients with the company’s new ...

Time May 19, 2022
arrow
News | Radiation Oncology

May 19, 2022 — Robert L. Bard, M.D., an ITN editorial advisory board member, received one of the highest achievements of ...

Time May 19, 2022
arrow
News | Radiation Therapy

May 18, 2022 — RaySearch announced that the treatment control system RayCommand is in clinical use at the innovative ...

Time May 18, 2022
arrow
News | Women's Health

May 18 2022 — Older breast cancer survivors with cardiometabolic risk factors who restricted food intake to eight hours ...

Time May 18, 2022
arrow
News | Radiation Oncology

May 17, 2022 — Radiation oncologists will meet with congressional leaders and staff today to ask for their support of ...

Time May 17, 2022
arrow
Videos | Proton Therapy

John C. Breneman, M.D., medical director of the Cincinnati Children's/UC Health Proton Therapy Center, and the principal ...

Time May 16, 2022
arrow
News | Focused Ultrasound Therapy

May 12, 2022 — UVA Health and the Charlottesville-based Focused Ultrasound Foundation today announced the launch of the ...

Time May 12, 2022
arrow
News | Treatment Planning

May 11, 2022 — Elekta has evolved radiosurgery to an unprecedented level with the launch of Elekta Esprit. This latest ...

Time May 11, 2022
arrow
News | Medical 3-D Printing

May 11, 2022 — Adaptiiv Medical Technologies is collaborating with HP Inc. and Varian, a Siemens Healthineers company ...

Time May 11, 2022
arrow
News | Treatment Planning

May 10, 2022 — GE Healthcare is proud to announce that it has entered into an agreement to collaborate with RaySearch ...

Time May 10, 2022
arrow
Subscribe Now